On Wednesday, Mizuho Securities reiterated its Outperform rating on Align Technology (NASDAQ:ALGN) shares with a consistent price target of $250.00. Currently trading at $154.24, the stock sits near its 52-week low of $150.80, while analyst targets range from $150.54 to $290.00. According to InvestingPro data, nine analysts have recently revised their earnings expectations downward for the upcoming period. The focus was on the implications of recent global tariff updates and their potential impact on Align’s operations. Align Technology, known for its Invisalign clear aligners and iTero scanners, could see some effects due to changes in the tariff environment, as outlined by the Mizuho analyst.
The analyst highlighted three main points regarding the tariff situation. Firstly, the administration’s recent announcement exempting USMCA-compliant goods from tariffs in Mexico and Canada benefits Align, as their Invisalign products manufactured in Mexico fall under this agreement. This exemption could mitigate some of the potential tariff impacts on the company’s products entering the U.S. market.
Secondly, Align’s iTero scanners, which are produced in Israel, might face a new 17% tariff. This development is significant considering Align’s annual cost of goods sold (COGS) in its Systems & Services segment is approximately $250 million. However, it’s noted that only a portion of this segment will be affected by the new tariff.
Lastly, the analyst noted that the global tariffs could potentially level the competitive playing field within the dental and orthodontic markets, as most manufacturers are likely to experience increased tariff exposure. Despite the evolving global tariff landscape, the analyst has chosen not to alter the projections for Align Technology at this time.
Align Technology’s stock performance will continue to be observed by investors and analysts alike as the company navigates the changing tariff regulations. Mizuho’s reiteration of its Outperform rating indicates confidence in the company’s ability to manage these external challenges while maintaining its financial targets. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US equities.
In other recent news, Align Technology has introduced a new Invisalign product designed for younger patients with Class II malocclusions, featuring occlusal blocks to enhance treatment effectiveness. This innovation aims to streamline the process by reducing the need for multiple appliances and is now available in Australia, New Zealand, and select regions, with a broader rollout expected in 2025. Meanwhile, Mizuho Securities has adjusted its financial outlook for Align Technology, lowering the stock price target to $250 while maintaining an Outperform rating, citing cautiousness regarding tariffs in Mexico and foreign exchange impacts.
Additionally, Stifel analysts have maintained a Buy rating with a $275 price target, highlighting a stabilization in Align’s market share, particularly in China, despite competitive pressures from Angelalign. Piper Sandler has also revised their price target for Align Technology to $235, maintaining a Neutral rating due to a recent decline in aligner volumes, influenced by weather-related disruptions. They noted that while challenges in demand persist, other aspects of Align’s business, such as international volumes and profit margins, are performing well.
Stifel further emphasized Align’s year-over-year revenue growth of 16% and favorable foreign exchange rates, although they noted concerns over increased promotional spending and rising days sales outstanding. Despite these mixed signals, Stifel remains optimistic about Align’s future prospects. Investors are advised to consider these recent developments as they evaluate Align Technology’s performance and outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.